Three cases of refractory bullous pemphigoid in the elderly treated successfully with ultra-low-dose rituximab.
J Dermatol
; 50(4): 561-564, 2023 Apr.
Article
in En
| MEDLINE
| ID: mdl-36539929
ABSTRACT
Rituximab has proven effective for the treatment of steroid-refractory bullous pemphigoid (BP), but there is controversy over the dosing protocol. We report three cases of refractory BP treated successfully with ultra-low-dose rituximab (100 mg weekly for 4 weeks). Our cases confirmed the efficacy and good follow-up outcomes of this treatment strategy for refractory BP. The ultra-low-dose rituximab regimen (100 mg weekly for 4 weeks) may be a useful alternative therapy in patients with refractory BP.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pemphigoid, Bullous
Type of study:
Guideline
Limits:
Aged
/
Humans
Language:
En
Journal:
J Dermatol
Year:
2023
Type:
Article
Affiliation country:
China